GGrantIndex
Sort

82,697 grants matching vaccine development

Chemoprophylaxis and HIV Host Interactions

$802,225
J. David Gladstone Institutes · R01 · FY2005 · AI

Immunotherapy to prevent drug-resistant tuberculosis

$802,216
Rhea N Coler · Access To Advanced Health Institute · R01 · FY2019 · AI

Structural mechanisms of bacteriophage infection and assembly

$802,161
Brian Kelch · University Of Massachusetts Medical School · · FY2024 · BIO

The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis

$802,099
Chetan Seshadri · University Of Washington · R01 · FY2024 · AI

Reactions And Immunochemistry Of Carbohydrates

$802,050
Pavol Kovac · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2013 · DK

Chemoattractant-based immunotherapeutics to modulate immune and cancer cells

$802,045
Arya Arya · Aging · Z01 · FY2007 · AG

Enhancing Discovery of HIV Host Genetics using Drug Abuse and other Interactions

$801,992
Eric O Johnson · Research Triangle Institute · R01 · FY2015 · DA

Development of an oral liver-targeted prime-and-trap malaria vaccine

$801,878
Sean C Murphy · University Of Washington · U01 · FY2021 · AI

Mechanisms of Enhanced Neutralizing Antibody Responses to Rhinovirus C

$801,850
Yury A Bochkov · University Of Wisconsin-Madison · R01 · FY2022 · AI

North-Central California-Center For AIDS Research

$801,832
University Of California Davis · P30 · FY2002 · AI

DEVELOPMENT OF VACCINES FOR ORAL CARCINOMA

$801,575
University Of Pittsburgh At Pittsburgh · P01 · FY2000 · DE

Understanding and optimizing antibody-based interventions against neonatal HSV infection

$801,565
Margaret E Ackerman · Dartmouth College · R01 · FY2023 · AI

The Role of Lipid-specific T cells in Mediating Protection Against M. tuberculosis

$801,468
Chetan Seshadri · University Of Washington · R01 · FY2021 · AI

HIV B-Cell Lineage Vaccine Design Based on Replicating SAd and Env Protein in NHP

$801,463
Jeffery Alexander · Paxvax, Inc. · R44 · FY2015 · AI

Liver resident memory for malaria

$801,401
Sean C Murphy · University Of Washington · R01 · FY2022 · AI

Reservoir Targeted Vaccine fo rthe Control of Lyme Borreliosis

$801,374
Maria Gomes-Solecki · University Of Tennessee Health Sci Ctr · U01 · FY2008 · CK

Mechanisms of mucosal protection induced by attenuated SIV

$801,307
R. Paul Johnson · Harvard Medical School · P01 · FY2011 · AI

Maturation of human humoral immunity through repeat malaria challenges

$801,244
Kim C Williamson · Henry M. Jackson Fdn For The Adv Mil/Med · R01 · FY2023 · AI

Impact of HIV, oral microbiome and mycobiome on oral HPV persistence

$801,143
Robert D. Burk · Albert Einstein College Of Medicine · R01 · FY2024 · DE

Development of highly potent human monoclonal for RSV immuno-prophylaxis

$801,020
Larry Zeitlin · Mapp Biopharmaceutical, Inc. · R44 · FY2021 · AI

MICROCHIP DRUG DELIVERY SYSTEM

$801,006
Massachusetts Institute Of Technology · R24 · FY2002 · AI

EFFECT OF A MULTIPEPTIDE KRAS VACCINE IN THE PREVENTION OF PANCREATIC CANCER DRIVEN BY KRAS ONCOPROTEIN HHSN2612015000371 TORFP: 2017-E02

$800,994
Ming You · Medical College Of Wisconsin · N01 · FY2017 · CA

The Impacts of Adverse Provider Conditions on Provider Bias and Health Disparities

$800,983
Anastasia Makhanova · University Of Arkansas At Fayetteville · R01 · FY2024 · MD

Targeting the Epigenome for Lung Cancer Therapy

$800,874
David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2010 · CA

A prophylactic vaccine to prevent colonization by Pseudomonas aeruginosa

$800,748
Wendy L Picking · University Of Missouri-Columbia · R01 · FY2023 · AI